The birth-control interaction that only one of these drugs has
Two drugs sold side by side on the same telehealth menus carry completely different instructions about birth control, and almost nobody is told which one they are on. The tirzepatide label says a single 5 mg dose cut peak ethinyl estradiol concentration by 59%, and tells patients on oral contraceptives to switch to a non-oral method or add a barrier one for four weeks after starting and after every dose increase. The word contraception does not appear on the semaglutide label at all.
What this comes down to
- The tirzepatide label instructs patients using oral hormonal contraceptives to switch to a non-oral method, or add a barrier method, for four weeks after initiation and for four weeks after each dose escalation. Non-oral hormonal contraceptives are not affected.
- The pharmacokinetic basis is on the same label: after a first 5 mg dose, peak concentrations of ethinyl estradiol, norgestimate and norelgestromin fell by 59%, 66% and 55%.
- The semaglutide label contains no contraception instruction. Searching the full prescribing information for the word returns nothing.
- Both labels say to stop for pregnancy. Semaglutide's says to discontinue at least two months before a planned pregnancy because of the drug's long half-life; tirzepatide's says to discontinue when a pregnancy is recognized.
The interaction, in the label's own numbers
Tirzepatide delays gastric emptying, and the delay is largest after the first dose. That single mechanism is behind two of the most consequential lines on these labels — this one, and the aspiration warning that applies before surgery. The label carries the pharmacokinetic consequence in its clinical pharmacology section: following a combined oral contraceptive given alongside a single 5 mg dose of tirzepatide, mean peak concentrations of ethinyl estradiol, norgestimate and norelgestromin were reduced by 59%, 66% and 55%, with overall exposure down by about a fifth and peak timing delayed by two and a half to four and a half hours[1]. The instruction that follows from it is specific.
“Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation. Hormonal contraceptives that are not administered orally should not be affected.”
[1]
The dose ladder on these drugs runs for months, and the instruction resets at every step up. Somebody titrating from 2.5 mg to 15 mg passes through several escalations, each of which restarts a four-week window. An intake flow that mentions this once at signup has told a patient about one of them.
The semaglutide label does not say this
Read end to end, the current semaglutide prescribing information contains no contraception instruction — the word does not occur anywhere in it[2]. It does warn that the drug delays gastric emptying and may affect absorption of other oral medications, and it asks for increased monitoring for oral drugs with a narrow therapeutic index, but it draws no contraceptive conclusion from that. The absence is a fact about the label, not a guarantee about the body, and the honest way to put it is that one manufacturer studied the interaction and wrote an instruction, and the other label carries neither.
That matters commercially because these two molecules are interchangeable in the way they are sold. Of the 257 sellers on our roster, 213 price semaglutide in some form, and a large share of those price tirzepatide too. A buyer switching between them on price — which switching providers shows is routine — is also switching between a label with a contraceptive instruction and a label without one.
What both labels say about pregnancy
The semaglutide label states that weight loss offers no benefit to a pregnant patient and may cause fetal harm, that available pharmacovigilance and trial data are insufficient to establish a drug-associated risk of major birth defects or miscarriage, and that because of the potential for fetal harm the drug should be discontinued at least two months before a planned pregnancy, to account for its long half-life[2]. The tirzepatide label's summary line is shorter: it may cause fetal harm, and when pregnancy is recognized, discontinue[1]. Both maintain pregnancy exposure registries, which exist because the trials excluded the population. This is the second of the two places where these labels stop cautioning and start prohibiting; the boxed warning is the first.
What has accumulated since is observational. A 2026 systematic review and meta-analysis pooled seven cohort studies covering more than 40,000 exposed pregnancies and found no statistically significant increase in any congenital malformation with exposure at any point in pregnancy, an odds ratio of 1.11, nor in major congenital malformations with first-trimester exposure, an odds ratio of 1.39 with a confidence interval crossing one[3]. Its authors call the evidence cautiously reassuring and rate its certainty low, and they flag that a signal for urinary malformations rested on unadjusted estimates only. That is what the field looks like when trials exclude the population: eighty-seven records mention these drugs and pregnancy, and two of them carry the randomized-trial tag[4].
PubMed, via the E-utilities API
(semaglutide[tiab] OR tirzepatide[tiab]) AND pregnan*[tiab] AND "randomized controlled trial"[pt] AND "humans"[mh]
Returned 2. Positive control — semaglutide, randomized-trial filter with no pregnancy term — returned 316 through the identical filter in the same session.
Eighty-seven records mention these drugs and pregnancy at all, and two of those carry the randomized-trial tag. That is the expected shape: pregnancy is an exclusion criterion in obesity trials, so the evidence that exists is built from registries and cohorts after the fact rather than from trials.
Questions people actually ask
Does tirzepatide affect birth control pills?
The label says it may reduce the efficacy of oral hormonal contraceptives because of delayed gastric emptying, and instructs patients to switch to a non-oral method or add a barrier method for four weeks after starting and for four weeks after each dose escalation. Non-oral hormonal methods are not affected.
Does semaglutide carry the same instruction?
No. The current semaglutide prescribing information contains no contraception instruction; the word does not appear in it. It does warn that the drug delays gastric emptying and may affect the absorption of other oral medications.
What do the labels say about stopping before pregnancy?
The semaglutide label says to discontinue at least two months before a planned pregnancy because of the drug's long half-life. The tirzepatide label says to discontinue when pregnancy is recognized. Both maintain pregnancy exposure registries.
What does the observational evidence show?
A 2026 meta-analysis of seven cohort studies covering more than 40,000 exposed pregnancies found no statistically significant increase in congenital malformations, stillbirth, spontaneous abortion, small-for-gestational-age or preterm birth. Its authors describe the evidence as cautiously reassuring and its certainty as low.
Sources
Every source here was fetched and read for this article, with the identifier taken off the record that came back and the claim it supports written down beside it. All of it was read in September 2026, the same session the rest of this page draws on.
- 1.ZEPBOUND (tirzepatide) injection — FDA prescribing information. DailyMed, National Library of Medicine, Structured Product Labeling, 2026. Source · Document dated August 2026The SPL with effective time 20260828 carries, in drug interactions and again in section 8.3, the instruction quoted above about oral hormonal contraceptives, a four-week barrier or non-oral window after initiation and after each dose escalation, and the statement that non-orally administered hormonal contraceptives should not be affected. Its clinical pharmacology section reports that following a combined oral contraceptive with a single 5 mg dose of tirzepatide, mean peak concentrations of ethinyl estradiol, norgestimate and norelgestromin fell by 59%, 66% and 55%, with mean AUC down 20%, 21% and 23% and peak timing delayed by 2.5 to 4.5 hours. Its pregnancy summary states the drug may cause fetal harm and to discontinue when pregnancy is recognized.
- 2.WEGOVY (semaglutide) injection and tablets — FDA prescribing information. DailyMed, National Library of Medicine, Structured Product Labeling, 2026. Source · Document dated June 2026A full-text search of the SPL with effective time 20260618 returned zero occurrences of the string contracept. Its pregnancy section states that weight loss offers no benefit to a pregnant patient and may cause fetal harm and that available pharmacovigilance and clinical trial data are insufficient to establish a drug-associated risk of major birth defects or miscarriage; section 8.3 directs discontinuation at least two months before a planned pregnancy to account for semaglutide's long half-life. Its drug interactions section states the drug delays gastric emptying and may impact absorption of concomitantly administered oral medications.
- 3.Pregnancy outcomes following maternal GLP-1 receptor agonist exposure: a systematic review and meta-analysis. Scientific Reports, 2026. PMID 42420519 · doi:10.1038/s41598-026-61582-8Seven cohort studies encompassing over 40,000 exposed pregnancies, searched through January 2026. Exposure at any time during pregnancy was not associated with a statistically significant increase in any congenital malformation (OR 1.11, 95% CI 0.82-1.51); first-trimester exposure was not associated with a significant increase in major congenital malformations (OR 1.39, 95% CI 0.73-2.65); no significant increase was seen for stillbirth, spontaneous abortion, small for gestational age or preterm birth. A urinary malformation association (OR 1.24, 95% CI 1.05-1.47) rested exclusively on unadjusted data. The authors describe the findings as cautiously reassuring with low certainty of evidence.
- 4.PubMed, queried through the E-utilities API. National Library of Medicine, 2026. SourceOn 2026-09-12, semaglutide or tirzepatide with a pregnancy term through the randomized-trial and human-indexing filter returned 2, against 87 for the same drug and pregnancy terms without the trial filter and 316 for semaglutide through the identical trial filter.
Key figures